Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The health service was previously unable to offer the drug as it was deemed too expensive
Thursday 22 Jun 2017 Author: Lisa-Marie Janes

The NHS will now offer a £90,000 breast cancer drug from Switzerland-listed pharmaceutical giant Roche, having previously considered the product to be too expensive.

Kadcyla is used to treat HER2-positive breast cancer that has spread to other parts of the body, which cannot be surgically removed and has stopped responding to initial treatment.

Shares in Roche have increased by 63% to CHF255.70 over the past five years.

‹ Previous2017-06-22Next ›